







Deep Antibody Pipeline of Differentiated Candidates

Program	Indication			Preclinical	Phase 1	Phase 2	Phase 3	Registration	Partner	
Efgartigimod	IV	MG		[Green bar]						
	SC	MG		[Green bar]						
	IV	ITP		[Blue bar]						
	SC	ITP		[Blue bar]						
	SC	PV		[Dark Blue bar]						
	SC	CIDP		[Green bar]						
	SC	Fifth Indication		[Green bar]						
	SC	Sixth Indication		[Grey bar]						
Cusatuzumab	+ AZA	Newly diag. AML (unfit)	CULMINATE	[Blue bar]						Janssen
	+ AZA + VEN	Newly diag. AML (unfit)	ELEVATE	[Blue bar]						Janssen
ARGX-117	IV + SC	Autoimmune (MMN)		[Green bar]						
	IV + SC	Kidney		[Light Blue bar]						
ARGX-118		Airway Inflammation		[Grey bar]						
ARGX-119		Neuromuscular indications		[Green bar]						
ARGX-120		Undisclosed		[Grey bar]						

Key:  NEURO  HEME  SKIN  KIDNEY